Antibodies elicited by the widely deployed rVSV-EBOV Ebola virus vaccine mirror those of disease survivors, animal models and other vaccine platforms. Notably, neutralizing antibodies are consistently elicited from a recurring pair of germline genes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ehrhardt, S. A. Nat. Med. s41591-019-0602-4 (2019).
Corti, D. et al. Science 351, 1339–1342 (2016).
Misasi, J. et al. Science 351, 1343–1346 (2016).
Davis, C. W. et al. Cell 177, 1566–1582 (2019).
Saphire, E. O. et al. Cell 174, 938–952 (2018).
Bornholdt, Z. A. et al. Science 351, 1078–1083 (2016).
Rijal, P. et al. Cell Rep. 27, 172–186.e7 (2019).
Henao-Restrepo, A. M. et al. Lancet 389, 505–518 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Saphire, E.O. A glimpse into immune responses evolving against Ebola virus. Nat Med 25, 1470–1471 (2019). https://doi.org/10.1038/s41591-019-0607-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-019-0607-z
